You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adenocarcinoma, Clear Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in Philadelphia (Metformin

Active, not recruiting
  • Breast Carcinoma
  • +4 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Feb 28, 2022

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)

Active, not recruiting
  • MSI-H Colorectal Cancer
  • +30 more
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in United

Active, not recruiting
  • Endometrial Clear Cell Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +5 more
  • Houston, Texas
  • +6 more
Dec 5, 2022

Ovarian Cancer, Recurrent Cancer Trial (CYH33)

Not yet recruiting
  • Ovarian Cancer
  • Recurrent Cancer
  • (no location specified)
Sep 5, 2021

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

ID TCRs From Renal Clear Cell Carcinoma Patients Responding to

Withdrawn
  • Renal Clear Cell Carcinoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    Aug 19, 2021

    Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

    Not yet recruiting
    • Fallopian Tube Carcinosarcoma
    • +10 more
    • Bevacizumab
    • +4 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 29, 2022

    Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma Trial in United States (PLX2853)

    Completed
    • Small Cell Lung Cancer
    • +7 more
    • Scottsdale, Arizona
    • +4 more
    Jul 20, 2022

    Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

    Completed
    Has Results
    • Endometrial Adenocarcinoma
    • +4 more
    • Akt Inhibitor MK2206
    • Laboratory Biomarker Analysis
    • Boston, Massachusetts
    • +6 more
    Jan 13, 2022

    Ovarian Cancer, Ovarian Tumors, Ovarian Carcinosarcoma Trial in Germany, United Kingdom (Paclitaxel, TAK228)

    Active, not recruiting
    • Ovarian Cancer
    • +9 more
    • Berlin, Germany
    • +14 more
    Mar 10, 2022

    Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer Trial in Canada,

    Active, not recruiting
    • Endometrial Clear Cell Adenocarcinoma
    • +5 more
    • Baltimore, Maryland
    • +6 more
    Apr 25, 2022

    Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

    Recruiting
    • Platinum-resistant Ovarian Cancer
    • +6 more
    • olvimulogene nanivacirepvec
    • +3 more
    • Orlando, Florida
      AdventHealth Cancer Institute
    Sep 1, 2022

    Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in

    Active, not recruiting
    Has Results
    • Endometrial Adenosquamous Carcinoma
    • +9 more
    • Cabozantinib S-malate
    • +2 more
    • Duarte, California
    • +18 more
    Oct 15, 2022

    Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Trial (KO-2806, Cabozantinib)

    Not yet recruiting
    • Solid Tumors With HRAS Alterations
    • +4 more
    • (no location specified)
    Aug 30, 2023

    Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

    Recruiting
    • Ovarian Cancer
    • +68 more
    • Phoenix, Arizona
    • +8 more
    Aug 18, 2022

    Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma Trial in United States (Nivolumab)

    Active, not recruiting
    • Uterine Cancer
    • +6 more
    • Basking Ridge, New Jersey
    • +7 more
    Apr 4, 2022

    Asian Multicenter Prospective Study of ctDNA Sequencing

    Recruiting
    • Cervical Cancer
    • +5 more
    • NGS analysis of ctDNA
    • Tokyo, Japan
    • +18 more
    Sep 28, 2022

    Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • +4 more
    • CTX131
    • Nashville, Tennessee
      Research Site 1
    Mar 21, 2023

    Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) Trial ([68Ga]Ga-DPI-4452,

    Not yet recruiting
    • Clear Cell Renal Cell Cancer (ccRCC)
    • +2 more
    • (no location specified)
    Jan 20, 2023

    Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston

    Recruiting
    • Advanced Endometrial Carcinoma
    • +36 more
    • Glutaminase Inhibitor IPN60090
    • Pembrolizumab
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 9, 2021

    Advanced Clear Cell Renal Cell Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder

    Active, not recruiting
    • Advanced Clear Cell Renal Cell Carcinoma
    • +35 more
    • Cabozantinib S-malate
    • +2 more
    • Duarte, California
    • +7 more
    Jan 3, 2023

    SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma Trial in Scottsdale (SP-2577, Pembrolizumab)

    Withdrawn
    • SCCOHT
    • +3 more
    • Scottsdale, Arizona
      HonorHealth Research Institute
    Feb 11, 2022

    Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma Trial in Palo Alto (drug, procedure,

    Active, not recruiting
    • Bladder Adenocarcinoma
    • +11 more
    • Palo Alto, California
      Stanford Cancer Institute Palo Alto
    Mar 25, 2022